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Multidrug-resistant (MDR) pathogens, particularly the ESKAPE group (Enterococcus
faecalis/faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, Escherichia coli, and Enterobacter spp.), have
become a public health threat worldwide. Development of new antimicrobial classes
and the use of drugs in combination are potential strategies to treat MDR ESKAPE
pathogen infections and promote optimal antimicrobial stewardship. Here, the in vitro
antimicrobial activity of robenidine analog NCL195 alone or in combination with different
concentrations of three outer membrane permeabilizers [ethylenediaminetetraacetic
acid (EDTA), polymyxin B nonapeptide (PMBN), and polymyxin B (PMB)] was
further evaluated against clinical isolates and reference strains of key Gram-negative
bacteria. NCL195 alone was bactericidal against Neisseria meningitidis and Neisseria
gonorrhoeae (MIC/MBC = 32 µg/mL) and demonstrated synergistic activity against
P. aeruginosa, E. coli, K. pneumoniae, and Enterobacter spp. strains in the presence
of subinhibitory concentrations of EDTA, PMBN, or PMB. The additive and/or
synergistic effects of NCL195 in combination with EDTA, PMBN, or PMB are
promising developments for a new chemical class scaffold to treat Gram-negative
infections. Tokuyasu cryo ultramicrotomy was used to visualize the effect of NCL195
on bioluminescent S. aureus membrane morphology. Additionally, NCL195’s favorable
pharmacokinetic and pharmacodynamic profile was further explored in in vivo safety
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studies in mice and preliminary efficacy studies against Gram-positive bacteria. Mice
administered two doses of NCL195 (50 mg/kg) by the intraperitoneal (IP) route 4 h
apart showed no adverse clinical effects and no observable histological effects in major
organs. In bioluminescent Streptococcus pneumoniae and S. aureus murine sepsis
challenge models, mice that received two 50 mg/kg doses of NCL195 4 or 6 h apart
exhibited significantly reduced bacterial loads and longer survival times than untreated
mice. However, further medicinal chemistry and pharmaceutical development to improve
potency, solubility, and selectivity is required before efficacy testing in Gram-negative
infection models.
Keywords: bacterial sepsis, bioluminescence, cryo-ultramicrotomy, membrane potential, multidrug resistance,
NCL195, polymyxin B, transmission electron microscopy
INTRODUCTION
Multidrug-resistant (MDR) pathogens, in particular the ESKAPE
pathogens (Enterococcus faecalis/faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, Escherichia coli, and Enterobacter spp.), are becoming
a public health threat in both hospitals and the community. In
particular, MDR Gram-negative ESKAPE pathogens significantly
impact the standard care of septic patients, owing to high
morbidity and mortality rates worldwide (ranging from 30 to
70%) (Giamarellou, 2010; Tamma et al., 2012; Bhattacharya,
2013; Zilberberg et al., 2014; Frieri et al., 2017). Studies have
consistently identified MDR Gram-negative ESKAPE pathogens
as the main cause of additional hospital-acquired infections, such
as respiratory tract, urinary tract, and postsurgical infections
(Cardoso et al., 2012; Pendleton et al., 2013; Santajit and
Indrawattana, 2016). Moreover, therapeutic options for these
infections are becoming more limited, resulting in high health
care costs resulting from protracted hospital stays (Ventola, 2015;
Centers for Disease Control and Prevention [CDCP], 2019).
In the past, the availability of new antimicrobials kept pace
with the evolution of antibiotic-resistant bacteria. However,
while there is an increasing trend of multidrug resistance
in both Gram-negative and Gram-positive bacteria, there has
been a significant global decline of investment into new drug
development (Livermore, 2012; Woolhouse and Farrar, 2014). As
a result, there are only a limited number of registered alternatives
for MDR Gram-negative ESKAPE pathogens and few truly novel
classes of antimicrobial agents undergoing preclinical testing in
the drug development pipeline (Lepore et al., 2019). Furthermore,
within the new classes of antimicrobial agents being developed,
most have activity only against Gram-positive pathogens, mainly
due to the presence of an outer membrane in Gram-negative
bacteria that deters the penetration and retention of antibiotics
(Pushpakom et al., 2019; Theuretzbacher et al., 2019).
Previously, our laboratory reported that NCL 195 (4,6-bis-
(2 -((E) -4-methylbenzylidene)hydrazinyl)pyrimidin-2-amine),
which was developed as a chemical analog of the anticoccidial
drug robenidine, possessed antimicrobial activity against MRSA,
vancomycin-resistant enterococci (VRE), and Streptococcus
pneumoniae. This selectivity is likely attributable to the mode
of action of NCL195, which permeabilizes the cytoplasmic
membrane of S. pneumoniae, VRE, and S. aureus, thereby
hindering the establishment and maintenance of essential
energy sources for cell functioning (Ogunniyi et al., 2017).
In the presence of subinhibitory concentrations of outer
membrane permeabilizers targeting the outer membrane of
bacteria (EDTA, PMBN, and PMB), NCL195 was bactericidal
against Gram-negative ESKAPE pathogens reference isolates
(A. baumannii, E. coli, K. pneumoniae, and P. aeruginosa)
(MICs of 0.25–8 µg/mL). Meanwhile, in the absence of these
outer membrane permeabilizers, NCL195 was also bactericidal
against eight Acinetobacter calcoaceticus isolates (MIC range
from 4 to 32 µg/mL) and one Acinetobacter anitratus isolate
(MIC = 4 µg/mL) (Abraham et al., 2016; Ogunniyi et al., 2017).
Here, we further evaluated the in vitro antimicrobial activity
of NCL195 in the presence of EDTA, PMBN, or PMB against
an expanded panel of Gram-negative pathogens isolated from
clinical cases. As a first proof of concept testing of the in vivo
efficacy of NCL195 against bacterial pathogens, we assessed
its in vivo safety and efficacy using our established/optimized
bioluminescent models of Gram-positive bacterial infection.
MATERIALS AND METHODS
Antimicrobial Agents
Analytical grade NCL195 (Figure 1) was synthesized in house
at the University of Newcastle as reported previously (Ogunniyi
et al., 2017) and stored in a sealed sample container out
of direct light at 4◦C at the study site at the Infectious
Diseases Laboratory, Roseworthy campus, the University of
Adelaide. Polymyxin B (PMB) and its derivative, polymyxin
B nonapeptide (PMBN), which is devoid of the N-terminal
fatty acyl chain and the L-α-γ-diaminobutyric acid residue (and
therefore lacks antibacterial activity except against Pseudomonas
spp.) (Velkov et al., 2010), were purchased from Sigma-Aldrich
(NSW, Australia). Stock solutions [containing 25.6 mg/mL of
PMBN or PMB in dimethyl sulfoxide (DMSO)] were prepared
and stored in 1-mL aliquots at−80◦C and defrosted immediately
prior to use. Ethylenediaminetetraacetic acid (EDTA, disodium
salt) was purchased from Chem-Supply Pty. Ltd., South Australia
and was dissolved in Milli-Q water to 200 mM.
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FIGURE 1 | Chemical structure of NCL195 (4,6-bis-(2-((E)-4-methylbenzylidene)hydrazinyl)pyrimidin-2-amine).
Bacterial Strains
A total of 101 Gram-negative bacteria were collected from
government, private, and university diagnostic laboratories
throughout Australia. These organisms were speciated using
biochemical testing and matrix-assisted laser desorption/
ionization–time-of-flight (MALDI-TOF) mass spectrometry
(Bruker, Preston, VIC, Australia). The organisms were 18
A. baumannii (including two reference strains A. baumannii
ATCC19606 and A. baumannii ATCC 12457), 10 A. calcoaceticus,
1 A. anitratus and 4 Neisseriae (N. meningitidis 423,
N. meningitidis 424, N. gonorrhoeae ATCC 16599, and
N. gonorrhoeae ATCC 49226). These organisms were kindly
provided by Professor Mary Barton (University of South
Australia) and the Australian Group on Antimicrobial
Resistance (AGAR) for testing the antimicrobial activity of
NCL195. Other antimicrobial-resistant bacteria comprising
18 K. pneumoniae, 18 E. coli, and 19 P. aeruginosa human
clinical isolates were obtained from the Australian Centre for
Antimicrobial Resistance Ecology (ACARE) collection. The
following additional 11 Gram-negative reference strains were
also used for combination experiments: E. coli ATCC 10763,
E. coli ATCC 25922, E. coli ATCC 11229, Pseudomonas putida
ATCC 17428, P. aeruginosa PAO1, P. aeruginosa ATCC 27853,
P. aeruginosa ATCC 33347, Proteus mirabilis ATCC 43071,
K. pneumoniae ATCC 13883, K. pneumoniae ATCC 33495, and
K. pneumoniae ATCC 4352. Bioluminescent E. coli (Xen14)
(PerkinElmer Inc., Waltham, MA, United States), derived
from the parental strain E. coli WS2572, and bioluminescent
P. aeruginosa (Xen41) (PerkinElmer Inc., Waltham, MA,
United States), derived from the parental strain P. aeruginosa
PAO1, were used for the time-dependent killing assays.
For in vivo efficacy evaluation of NCL195, bioluminescent
S. aureus (Xen29), derived from the parental strain S. aureus
ATCC 12600 (PerkinElmer Inc., Waltham, MA, United States),
and bioluminescent S. pneumoniae, derived from the
parental strain S. pneumoniae D39 (D39LUX) (Henken et al.,
2010), were used.
Antimicrobial Susceptibility Testing
Minimum inhibitory concentrations (MICs) were determined
in round-bottom 96-well microtiter trays (Sarstedt 82.1582.001),
using the modified broth microdilution method recommended
by the Clinical and Laboratory Standards Institute [CLSI],
2017. Testing concentrations were as follows: NCL195: 256–
0.25 µg/mL; EDTA: 3,800–45 µg/mL; PMBN: 32–0.06 µg/mL;
PMB: 32–0.06 µg/mL. Luria–Bertani (LB) broth (Oxoid, VIC,
Australia) was used instead of cation-adjusted Mueller–Hinton
broth as it was shown previously that robenidine can chelate
calcium ions resulting in loss of activity. In addition, twofold
serial dilutions of NCL195 were performed in 100% DMSO,
with 1 µL added to each well, as NCL compounds have very
low solubility in aqueous environments (Abraham et al., 2016).
The MICs for ampicillin, gentamicin, and apramycin against
each isolate were determined for each test to serve as an
internal quality control. The MICs of isolates were determined
by visual reading and using an EnSpire Multimode Plate Reader
2300 at A600 nm. MIC50, MIC90, and MIC ranges for NCL195,




The minimum bactericidal concentration (MBC) of NCL195
alone or in combination with EDTA, PMBN, or PMB was
determined against both Gram-positive and Gram-negative
bacteria. Briefly, 10-µL aliquots from each duplicate well from
the MIC assays (starting from the MIC for each compound) were
inoculated onto a sheep blood agar (SBA) plate and incubated at
37◦C. Plates were examined at 24 and 48 h and the MBC was
recorded as the lowest concentration of each test compound at
which a 99.95% colony count reduction was observed on the plate
(Clinical and Laboratory Standards Institute [CLSI], 2017).
Synergy Testing by Checkerboard
Microdilution and Dose Reduction
Analysis
To assess potential synergistic activity of NCL195, MICs for a
range of Gram-negative ATCC strains and clinical isolates of
K. pneumoniae, E. coli, A. baumannii, and P. aeruginosa were
determined in the presence or absence of 23.2–11,400 µg/mL
(0.06–30 mM) of EDTA and 0.25–128 µg/mL of PMBN or
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PMB in a modified standard checkerboard assay as described
previously (Hamoud et al., 2015; Khazandi et al., 2019). Briefly,
antimicrobial stock solutions were prepared at a concentration
of 25.6 mg/mL in DMSO for NCL195, 12.8 mg/mL in Milli-
Q water for PMBN and PMB, and 30 mM in Milli-Q water
for EDTA. Then, a twofold serial dilution of each antimicrobial
stock solution was prepared in its appropriate solvent from wells
12 to 3 (starting from 25.6 to 0.25 mg/mL for NCL195, 12.8
to 0.25 mg/mL for PMBN and PMB, and 30 to 0.06 mM for
EDTA). One microliter of each concentration was then added to
each well in the challenge plate using an electronic multichannel
pipette followed by 89 µL of the LB broth. Ten microliters
of bacterial suspension of 1.5 × 106 colony forming units per
milliliter (CFU/mL) was added to each well of the plate, which
was subsequently incubated at 37◦C for 24 h.
The fractional inhibitory concentration index (FICI) describes
the results of combination, and was calculated as follows: FICI
of combination = FIC A + FIC B. Where FIC A is the MIC
of NCL195 in the combination/MIC of NCL195 alone, FIC B is
the MIC of EDTA in the combination/MIC of EDTA alone. The
results indicate synergism when the corresponding FICI ≤ 0.5,
additivity when 0.5 < FICI ≤ 1, indifference when 1 < FICI ≤ 4,
and antagonism when the FICI > 4. In this study, the FICI
for NCL195 and PMBN against Gram-negative bacteria was
calculated to be zero (e.g., 1÷> 256 = 0), where they did not show
any antibacterial activity alone against Gram-negative bacteria at
the highest concentration (256 µg/mL).
The dose reduction index (DRI) shows the difference between
the effective doses in combination in comparison to its individual
dose. DRI was calculated as follows: DRI = MIC of drug
alone/MIC of drug in combination. Given that NCL195 and
PMBN did not show any antimicrobial activity against the
majority of Gram-negative bacteria, the highest concentration
of each compound tested against each isolate was used as
its MIC alone for calculating the DRI (e.g., MIC of NCL195
alone against E. coli 103 was >256 µg/mL and its MIC in
combination with PMBN was 1 µg/mL; DRI = 256/1). DRI is very
important clinically when the dose reduction is associated with
a toxicity reduction without changing efficacy (Eid et al., 2012).
Commonly, a DRI higher than 1 is considered beneficial.
Time-Dependent Killing Assays
Initial time kill assays were performed (in duplicate) for
the NCL195 in the presence of PMB against a range of
human ESKAPE pathogen reference strains (E. coli ATCC
25922, P. aeruginosa PAO1, K. pneumoniae ATCC 33495,
and A. baumannii ATCC 19606) as described previously
(Clinical and Laboratory Standards Institute [CLSI], 2017)
with slight modifications. Briefly, a few colonies of each
strain from overnight SBA plates were emulsified in normal
saline and adjusted to A600 nm = 0.10 (equivalent to approx.
5 × 107 CFU/mL) and the bacterial suspensions were further
diluted 1:20 in saline. NCL195 and PMB were serially diluted
in 100% DMSO or Milli-Q water at 100 × the final
desired concentration and a 100-µL aliquot of appropriate
concentrations added to each 10 mL preparation. NCL195 and
PMB solutions were prepared in 10-mL volumes at MIC and
2 × MIC concentrations in LB broth. After addition of the
inoculum dose to each tube, duplicate cultures were incubated
at 37◦C, with samples withdrawn at 0, 0.5, 1, 2, 4, 6, 8, and 24 h,
serially diluted 10-fold, and plated on SBA overnight at 37◦C for
bacterial enumeration. The time kill assay was further refined
by testing the NCL195-PMB combination on bioluminescent
E. coli WS2572 (Xen14) and bioluminescent P. aeruginosa PAO1
(Xen41). According to CLSI, an antimicrobial agent is considered
bactericidal if it causes a ≥3 × log10 (99.95%) reduction in
CFU/mL after 18–24 h of incubation, and the combination is
considered synergistic when it causes a ≥2 × log10 reduction in
CFU/mL compared with either constituent alone.
Dual Mechanism of Action of
NCL195-PMB Combination
Polymyxin B has been demonstrated to disrupt the outer
membrane of Gram-negative bacteria (Lin et al., 2018, 2019;
Wang et al., 2020), while NCL195 has been shown to disrupt the
inner membrane potential of Gram-positive bacteria (Ogunniyi
et al., 2017). Thus, we hypothesized that a combination of PMB
and NCL195 will disrupt the outer membrane (PMB), allowing
penetration of NCL195 into the inner membrane, as shown
in Figure 2.
To prove this hypothesis, the membrane potential of E. coli
Xen14 cells was measured by fluorescence spectrometry in a LS 55
Fluorescence Spectrometer (PerkinElmer) using the fluorescent
membrane potential probe 3,3-diethyloxacarbocyanine iodide
[DiOC2(3)]. A combination of Gram-negative and Gram-
positive membrane potential measurement approaches was used
as described previously (Venter et al., 2003; Ogunniyi et al., 2017;
Wang et al., 2020). Briefly, E. coli Xen14 cells were prepared and
resuspended in 50 mM potassium phosphate buffer (pH 7.0) to
A600 nm = 5. PMB was used at 6.4 µg/mL, while NCL195 was used
at either 12.8 or 25.6 µg/mL. The test compounds and/or their
combination were incubated with the cells for either 5 or 30 min,
after which DiOC2(3) was added and the fluorescence monitored
until it plateaued. The cells were then energized by the addition
of glucose to establish a proton motive force (negative and basic
inside the cell). This led to an increase in fluorescence associated
with aggregation of the DiOC2(3). The membrane potential was
then disrupted by the addition of the proton ionophore carbonyl
cyanide m-chlorophenyl hydrazone (CCCP).
Transmission Electron Microscopy to
Visualize the Effect of NCL195 on
Bioluminescent S. aureus ATCC12600
(Xen29) Cell Membrane
Treatment Preparation
Xen29 was grown on horse blood agar containing 200 µg/mL of
kanamycin at 37◦C. A single colony was transferred to 10 mL
of LB broth in 50-mL Falcon tubes and grown at 37◦C under
continuous agitation in a reciprocating shaker at 150 rpm. The
overnight culture was then diluted 1:30 in 40 mL of LB broth
and incubated at 37◦C in 50-mL Falcon tubes as previously
described until A600 nm = 0.1 was obtained. Xen29 was incubated
with NCL195 (2 and 4 µg/mL) for 1 h at 37◦C, with manual
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FIGURE 2 | Proposed dual mechanism of action of NCL195 in combination with PMB on Gram-negative bacteria. NCL195 alone is unable to penetrate the outer
membrane of Gram-negative bacteria; however, a subinhibitory concentration of PMB can permeabilize the outer membrane and allow penetration of NCL195,
resulting in disruption of the inner membrane.
mixing every 10 min. A treatment time of 1 h was chosen
based on the time kill kinetic and MIC of NCL195 to ensure
Xen29 cells were not killed at the time of harvest. Cells were
harvested by centrifugation at 2900 × g for 5 min at 4◦C.
Control cells were harvested at A600 nm = 0.1 without the
addition of compound. Cells were washed twice in phosphate-
buffered saline (PBS) buffer; fixed in 4.0% formaldehyde, 1.25%
glutaraldehyde, 0.01 M CaCl2, 4% sucrose, and in the presence
of 0.075% ruthenium red and 0.075% L-lysine acetate (to
stabilize the peptidoglycan layer and aid in locating the bacteria
during sectioning); and then stored at 4◦C until processing
for transmission electron microscopy (TEM). Thereafter, cells
were washed twice in PBS and embedded in 12% gelatin. Small
gelatin blocks containing bacteria (<1 mm3) were cut and
infiltrated with 2.3 M sucrose in PBS overnight at 4◦C with
gentle rocking. Blocks were stored in 2.3 M sucrose at 4◦C prior
to sectioning.
Cryo-Ultramicrotomy and TEM
Blocks were transferred to aluminum cryo-sectioning pins (Leica)
and quickly plunge-frozen in liquid nitrogen. Thin cryo-sections
(80 nm) were cut at −100◦C with an EM-UC6/FC7 cryo-
ultramicrotome (Leica) using a cryo-diamond knife (Diatome).
Cryo-sections were removed from the knife with 2.3 M sucrose
using a wire loop and transferred to formvar/carbon-coated,
plasma cleaned, 200-mesh copper EM grids (Proscitech). Grids
were stored in an airtight container on sucrose droplets at 4◦C.
To stain, grids were floated face down on 2% gelatin for 30 min at
37◦C before washing in PBS (3 min × 2 min) and staining with
2% uranyloxalicacetate, pH 7 (5 min, room temperature) and
methyl cellulose–uranyl acetate pH 4 on ice (10 min). Grids were
looped out, drained, and allowed to dry. Samples were imaged
with a Tecnai G2 Spirit electron microscope (FEI Company)
operated at 100 kV at Adelaide Microscopy, the University of
Adelaide, South Australia.
Ethics Statement
For NCL195 safety and efficacy testing experiments, outbred 5-
to 6-week-old male CD1 (Swiss) mice (weighing between 25 and
32 g), obtained from the Laboratory Animal Services breeding
facility of the University of Adelaide, were used. Mice had access
to food and water ad libitum throughout the experiments. The
Animal Ethics Committee of the University of Adelaide (approval
numbers S-2013-053 and S-2015-151) reviewed and approved
all animal experiments. The study was conducted in compliance
with the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes (8th edition, 2013) and the South
Australian Animal Welfare Act 1985.
Safety Testing of NCL195 Following
Parenteral Administration
We previously determined the pharmacokinetic parameters for
NCL195 after a single intraperitoneal administration of 43 mg/kg
NCL195 dissolved in 20% (v/v) DMSO in PEG400 with no
observed adverse reactions or compound-related side effects
(Ogunniyi et al., 2017). It was then assumed that a twofold
increase in dose would result in a proportional increase in
NCL195 exposure. To test that a two-dose regime would be
safe to administer to mice, a safety study was conducted by
administering two intraperitoneal doses of NCL195 at either
10 mg/kg or 50 mg/kg 4 h apart to three mice, using two
intraperitoneal doses of either PBS or 6 mg/kg daptomycin as
controls. Mice were observed for clinical signs and data recorded
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on a Clinical Record Sheet (CRS) approved by the Animal Ethics
Committee of the University of Adelaide. At the conclusion of
the experiment, mice were humanely killed and sections of liver,
kidneys, spleen, heart, and brain were collected and subjected to
histopathological examination.
Histopathological Examination
Mouse tissues (including liver, spleen, kidneys, heart, and
brain) collected from the intraperitoneal safety challenge
were fixed in 10% neutral-buffered formalin and processed
routinely. The specimens were embedded in paraffin
blocks and sections of 4 µm thickness were cut using a
microtome. Hematoxylin and eosin staining of the sections was
performed and the slides were observed and recorded under
light microscopy.
Efficacy Testing of NCL195 Following
Systemic Challenge of Mice With
Bioluminescent Gram-Positive Bacteria
For the NCL195 efficacy testing experiments against
S. pneumoniae challenge, luminescent strain D39 (D39LUX),
which emits light constitutively at λmax = 490 nm in metabolically
active cells, was used, and has been described previously (Henken
et al., 2010). Before infection, D39LUX was grown statically
in serum broth (10% heat-inactivated horse serum in nutrient
broth) at 37◦C, 5% CO2 to A600 nm of 0.16 (equivalent to
approx. 5 × 107 CFU/mL). Three groups of mice (n = 10
mice per group) were then challenged intraperitoneally with
approx. 2.5 × 104 CFU of D39LUX in 100 µL of serum
broth. At 12 h postinfection, the conditions of all mice in
each group were recorded on a CRS approved by the Animal
Ethics Committee of the University of Adelaide. All mice were
subjected to bioluminescent imaging in a ventral position
on either the Xenogen IVIS 100 system (Xenogen) or the
IVIS Lumina XRMS Series III system (Caliper Life Sciences).
Immediately after, group 1 mice were administered the drug
vehicle only, group 2 received NCL195 at 50 mg/kg i.p., while
group 3 received daptomycin at 6 mg/kg i.p. The clinical
conditions of all mice were then closely monitored every 2 h,
and at 18 h postinfection, all animals in each group were
again subjected to bioluminescent imaging. Thereafter, group
1 mice received a second dose of drug vehicle only, while
group 2 received a second dose of NCL195 at 50 mg/kg, and
mice were further monitored frequently for signs of distress.
The daptomycin-treated group did not receive a second dose,
as their clinical conditions and bioluminescent imaging data
indicated a healthy status. At 24, 30, and 60 h postinfection,
mice were further subjected to bioluminescent imaging, and
mice that had become moribund or showed any evidence of
distress [such as loss of balance, extreme hyperactivity, severe
weight loss (>20% body weight), ear temperature falling below
24◦C, paralysis, or extreme reluctance or inability to move
freely, and/or refusal or inability to eat or drink] were humanely
killed by cervical dislocation. A second experiment (n = 5)
was also performed essentially as described above, but with
antimicrobial administration at 8 and 12 h postinfection to
assess whether earlier intervention might further prolong the
survival times for mice.
For the NCL195 efficacy testing experiments against S. aureus,
luminescent ATCC12600 strain (Xen29, PerkinElmer) was used,
essentially as described previously (Ogunniyi et al., 2018). Briefly,
bacteria were grown in LB broth at 37◦C to A600 nm of 0.5
(equivalent to approx. 1.5 × 108 CFU/mL). Three groups of
mice (n = 5 mice per group) were challenged intraperitoneally
with approx. 2.5 × 107 CFU of Xen29 in 200 µL of PBS
containing 3% hog gastric mucin type III (Sigma-Aldrich). At
2 h postinfection, all mice were subjected to bioluminescent
imaging in both ventral and dorsal positions on the IVIS Lumina
XRMS Series III system. Immediately after, group 1 mice received
the drug vehicle only, group 2 received NCL195 at 50 mg/kg
i.p., while group 3 received daptomycin at 6 mg/kg i.p. The
clinical conditions of all mice were closely monitored, and at
6 h postinfection, all animals in each group were subjected
to bioluminescent imaging, after which a second dose of drug
vehicle only, NCL195, or daptomycin was administered. Mice
were further monitored frequently for signs of distress and
those that had become moribund or showed any evidence
of distress were humanely killed by cervical dislocation. At
10 and 16 postinfection, living mice were further subjected
to bioluminescence imaging. In all experiments, signals were
collected from a defined region of interest and total flux
intensities (photons/s) analyzed using Living Image Software 2.5
(for IVIS 100) and 4.4 (for Lumina XRMS). Differences in median
survival times (time to moribund) for mice between groups
were analyzed by the log-rank (Mantel–Cox) tests. Differences
in luminescence signals between groups were compared by
multiple t-tests.
RESULTS
NCL195 Alone Shows Antimicrobial
Activity Against N. meningitidis and
N. gonorrhoeae
The activity of NCL195 against a range of Gram-negative
bacteria (A. baumannii ATCC 19606, A. baumannii ATCC
12457, E. coli ATCC 10763, E. coli ATCC 25922, K. pneumoniae
ATCC 33495, K. pneumoniae ATCC 4352, P. aeruginosa ATCC
27853, P. aeruginosa PAO1, N. meningitidis 423, N. meningitidis
424, N. gonorrhoeae ATCC 16599, and N. gonorrhoeae ATCC
49226) was investigated. The results show that NCL195 alone
demonstrated antimicrobial activity against the Neisseria isolates
and type strains tested at 32 µg/mL, but no activity was
observed against the other Gram-negative bacteria tested at up
to 256 µg/mL (data not shown).
Combination of NCL195 With EDTA
Demonstrates Antimicrobial Activity
Against Gram-Negative Pathogen Strains
The modified checkerboard assay was used to assess the
combination of NCL195 and EDTA against a range of
human Gram-negative pathogen reference strains (E. coli
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ATCC 25922, E. coli ATCC 11229, P. putida ATCC 17428,
P. aeruginosa PAO1, P. aeruginosa ATCC 27853, Proteus
mirabilis ATCC 43071, K. pneumoniae ATCC 13883,
A. baumannii ATCC19606, and A. baumannii ATCC 12457),
and one A. calcoaceticus clinical isolate. The results indicate
a synergistic interaction of NCL195 and EDTA for E. coli
ATCC 25922, E. coli ATCC 11229, K. pneumoniae ATCC
13883, P. putida ATCC 17428, P. aeruginosa PAO1, and
P. aeruginosa ATCC 27853. An additive interaction was observed
for P. mirabilis ATCC 43071, A. baumannii ATCC19606,
A. baumannii ATCC 12457, and the clinical A. calcoaceticus
isolate (Table 1).
Combination of NCL195 With Polymyxins
(PMBN and PMB) Also Demonstrates
Synergistic Activity Against a Range of
Gram-Negative ESKAPE Pathogen
Reference Strains
The antimicrobial activity of NCL195 in the presence of
PMBN was investigated against a range of human ESKAPE
pathogen reference strains: 3 E. coli strains (E. coli ATCC
25922, E. coli ATCC 11229, and E. coli ATCC 10763), 3
P. aeruginosa strains (P. aeruginosa ATCC 27853, P. aeruginosa
ATCC 33347, and P. aeruginosa PAO1), 2 K. pneumoniae strains
(K. pneumoniae ATCC 33495 and K. pneumoniae ATCC 4352),
and 2 A. baumannii strains (A. baumannii ATCC 19606 and
A. baumannii ATCC 12457). The combination of NCL195 and
PMBN resulted in a synergistic interaction against E. coli ATCC
11229, P. aeruginosa ATCC 27853, and K. pneumoniae ATCC
4352. An additive interaction was recorded against P. aeruginosa
PAO1 (Table 2). No interaction was detected against the rest of
the reference strains tested.
Owing to the high cost of PMBN, we hypothesized that PMB
would be a more easily acquired and cost-effective choice of outer
membrane permeabilizer with similar efficacy in combination
with NCL195 against Gram-negative bacteria. Therefore, the
antimicrobial activity of NCL195 and PMB in combination
was tested against a larger range of human ESKAPE pathogen
isolates (18 K. pneumoniae clinical isolates plus K. pneumoniae
ATCC 33495 and K. pneumoniae ATCC 4352, 18 E. coli clinical
isolates plus E. coli ATCC 10763 and E. coli ATCC 25922, 16
A. baumannii clinical isolates plus A. baumannii ATCC 19606
and A. baumannii ATCC 12457, 19 P. aeruginosa clinical isolates
plus P. aeruginosa PAO1) (Table 3). The results revealed a
synergistic interaction of NCL195 and PMB in combination
against all Gram-negative isolates tested (reducing the MIC
of NCL195 by 64- to 1,024-fold against all Gram-negative
species tested).
Time Kill Kinetics of the Combination of
NCL195 and PMB Shows Bactericidal
Antimicrobial Activity Against E. coli and
P. aeruginosa Reference Strains
Initial time kill kinetics of the NCL195-PMB combination against
E. coli ATCC 25922, P. aeruginosa PAO1, K. pneumoniae ATCC
33495, and A. baumannii ATCC 19606 showed rapid, time-
dependent killing of the bacteria (Supplementary Figure S1).
The assay was further refined using bioluminescent E. coli
WS2572 (Xen14) and bioluminescent P. aeruginosa PAO1
(Xen41). For Xen14, NCL195/PMB at 1/0.125 µg/mL showed
no antimicrobial activity; NCL195/PMB at 2/0.125 µg/mL
reduced the CFU/mL by 5 × log10 by 1 h post-treatment
but then growth started again after 8 h; NCL195/PMB at
1/0.25 µg/mL reduced the CFU/mL by 5 × log10 by 6 h post-
treatment but then growth started again after 8 h; NCL195/PMB
at 2/0.25 µg/mL reduced the CFU/mL by 5 × log10 by
30 min post-treatment and totally cleared the bacterial growth
(Figure 3A). For Xen41, NCL195/PMB at 2/1 µg/mL reduced
the CFU/ml by 5 × log10 within 1 h of treatment but then
growth started again after 8 h; NCL195/PMB at 4/1 µg/mL
reduced the CFU/mL by 5 × log10 by 30 min post-treatment
and totally cleared the bacterial growth; NCL195/PMB at
TABLE 1 | MIC values for NCL195 alone, EDTA alone, and in combination for Gram-negative bacteria reference strains and clinical isolates.
Isolates MIC (µg/mL; mM concentrations in parentheses) FICI DRI
Single drug Combination
EDTA NCL195 EDTA NCL195 EDTA:NCL195
E. coli ATCC 25922 3800 (10) >256 950 (2.5) 4 0.27a 4:64
E. coli ATCC 11229 950 (2.5) >256 228 (0.6) 8 0.27a 4:32
P. putida ATCC 17428 1900 (5) >256 950 (2.5) 1.25 0.50a 2:204
P. aeruginosa PAO1 1900 (5) >256 475 (1.25) 1.25 0.25a 4:204
P. aeruginosa ATCC 27853 3800 (10) >256 1900 (5) 2 0.50a 2:128
P. mirabilis ATCC 43071 228 (0.6) >256 228 (0.6) 0.5 1.00b 1:512
K. pneumoniae ATCC 13883 11 400 (30) >256 3800 (10) 4 0.35a 3:64
A. baumannii ATCC19606 380 (1) >256 190 (0.5) 2 0.51b 2:128
A. baumannii ATCC 12457 190 (0.5) >256 95 (0.25) 4 0.52b 2:64
A. calcoaceticus (a clinical isolate) 228 (0.6) >256 228 (0.6) 8 1.00b 1:32
Synergy testing by checkerboard microdilution and dose reduction analysis. DRI, dose reduction index. aSynergistic effect. bAdditive effect. The results indicate synergism
when the corresponding FICI ≤ 0.5, additivity when 0.5 < FICI ≤ 1, indifference when 1 < FICI ≤ 4, and antagonism when the FICI > 4.
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TABLE 2 | MIC values for NCL195 alone and PMBN alone and in combination for Gram-negative bacteria reference strains and clinical isolates.
Isolates Single drug (µg/mL) Combination (µg/mL) FICI DRI
PMBN NCL195 PMBN NCL195 PMBN:NCL195
P. aeruginosa PAO1 1 >256 0.5 4 0.5a 2:64
P. aeruginosa ATCC 27853 2 >256 0.5 4 0.27a 4:64
E. coli ATCC 11229 >128 >256 8 32 0.19a 16:8
K. pneumoniae ATCC 4352 >128 >256 0.125 4 0.03a 1024:64
DRI, dose reduction index. aSynergism effect. The results indicate synergism when the corresponding FICI ≤ 0.5, additivity when 0.5 < FICI ≤ 1, indifference when
1 < FICI ≤ 4, and antagonism when the FICI > 4.
TABLE 3 | MIC range and MIC50, MIC90, and DRI values for NCL195 alone, PMB alone, and in combination against 20 K. pneumoniae, 20 E. coli, 18 A. baumannii, and
20 P. aeruginosa clinical isolates.
Isolates Value Antimicrobial concentration (µg/mL) Combination Effect DRI
Single drug Combination
PMB NCL195 PMB NCL195 PMB NCL195
K. pneumoniae (n = 20) MIC range 0.125–1 >256 0.06–0.5 0.25–4 Synergism 2–4 64–1024
MIC50 0.5 >256 0.125 2 4 128
MIC90 1 >256 0.25 4 2 64
E. coli (n = 20) MIC range 0.125–1 >256 0.06–0.125 0.25–2 Synergism 2–8 128–1024
MIC50 0.5 >256 0.06 1 8 256
MIC90 0.5 >256 0.125 2 4 128
A. baumannii (n = 18) MIC range 0.5–1 >256 0.125 0.5–4 Synergism 4–8 64–512
MIC50 1 >256 0.125 2 8 128
MIC90 1 >256 0.125 2 4 128
P. aeruginosa (n = 20) MIC range 0.25–1 >256 0.06–0.25 1–2 Synergism 4–8 128–256
MIC50 0.5 >256 0.125 1 4 256
MIC90 0.5 >256 0.125 2 4 128
1/2 µg/mL reduced the CFU/ml by 5 × log10 by 30 min
post-treatment but then growth started again after 8 h;
NCL195/PMB at 2/2 µg/mL reduced the CFU/mL by 5 × log10
by 30 min post-treatment and totally cleared the bacterial
growth (Figure 3B).
Combination of PMB and NCL195
Disrupts the Inner and Outer Membrane
Potential of E. coli
We tested the hypothesis that a combination of PMB and
NCL195 will disrupt the outer membrane (PMB), allowing
penetration of NCL195 into the inner membrane of Gram-
negative bacteria by measuring the membrane potential of E. coli
Xen14 cells using fluorescence spectrometry as described in
Section “Materials and Methods” (see section “Dual Mechanism
of Action of NCL195-PMB Combination”). We showed that
preincubation of the cells with PMB at 6.4 µg/mL permeabilized
the outer membrane so that greater quantities of the DIOC2(3)
could gain entry into the cells without affecting the inner
membrane (Figures 4A,B). Preincubation of the cells with the
NCL195 + PMB combination resulted in a time-dependent
and NCL195 concentration-dependent disruption of the inner
membrane potential, clearly demonstrating the dual mechanism
of action of NCL195-PMB combination.
NCL195 Exerts Its Antibacterial Action
on the Cell Membrane of S. aureus
We previously showed that NCL195 acts on the cell membranes
of S. pneumoniae (MIC range of 2–8 µg/ml) and S. aureus
(MIC range of 1–2 µg/mL) via disruption of the membrane
potential (Ogunniyi et al., 2017) and demonstrated changes
in the appearance and thickness of the NCL195-treated cell
membrane for S. pneumoniae by TEM, but this was not
carried out for S. aureus. In this study, we used Tokuyasu
ultrathin cryo-sections to visualize the effect of NCL195 on
bioluminescent S. aureus Xen29 membrane morphology. TEM
images showed optimal structural preservation with clear
delineation of the plasma membrane and cell wall peptidoglycan
layer. Samples treated with NCL195 clearly show perturbation
of the membrane consistent with its membrane-acting property.
In the treated sample, mesosome-like membrane structures were
also observed (Figure 5).
NCL195 Shows Systemic Safety in Mice
There were no observable histopathological changes in the heart,
liver, spleen, kidneys, or brain (not shown) of any of the mice
in the treated groups (NCL195 10 mg/kg, NCL195 50 mg/kg,
and daptomycin) compared to the control group treated with
PBS (Figure 6).
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FIGURE 3 | Time kill curves of NCL195 and PMB combinations against (A) bioluminescent E. coli (Xen14): NCL195/PMB: 1/0.125 µg/mL; NCL195/PMB:
2/0.125 µg/mL; NCL195/PMB: 1/0.25 µg/mL; NCL195/PMB: 2/0.125 µg/mL and (B) bioluminescent P. aeruginosa (Xen41): NCL195/PMB: 2/1 µg/mL;
NCL195/PMB: 4/1 µg/mL; NCL195/PMB: 1/2 µg/mL; NCL195/PMB: 2/2 µg/mL.
FIGURE 4 | Dual mechanism of action of NCL195-PMB combination. E. coli Xen14 cell suspensions were exposed to 6.4 µg/mL of NCL195 or 6.4 µg/mL of PMB
alone or a combination of NCL195 and PMB at the indicated concentrations for either 5 min (A) or 30 min (B) after which DiOC2(3) was added and the fluorescence
monitored until it plateaued. Cells were then reenergized with 0.5% glucose and the establishment of a membrane potential was measured as an increase in
fluorescence until it plateaued. The membrane potential was then disrupted by the addition of the proton ionophore (CCCP).
Treatment of Mice With NCL195 Reduces
S. pneumoniae and S. aureus
Populations and Significantly Prolongs
Survival Times
We evaluated the potential of NCL195 as a therapeutic
drug against systemic S. pneumoniae infection, using a well-
characterized luminescent strain (D39LUX) (Henken et al., 2010)
in an intraperitoneal sepsis challenge model. We found that
at 24 h postinfection, two doses of NCL195 at 50 mg/kg
i.p. (administered at 12 and 18 h postinfection) resulted in a
statistically significant reduction in S. pneumoniae populations
(p = 0.018, multiple t-tests; Figure 7A) and a concomitant
significant increase in median survival time compared to
the vehicle only control in this model (p = 0.008; Mantel–
Cox test; Figure 7B). In a repeat experiment, intraperitoneal
administration of two doses of NCL195 at 50 mg/kg at 8
and 12 h postinfection resulted in an earlier and statistically
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FIGURE 5 | Morphology of bioluminescent S. aureus Xen29 prepared using Tokuyasu cryo-ultramicrotomy and visualized by TEM. (A1–A3) Xen29 without
treatment. (B1–B3) Xen29 treated with NCL195 at 2 µg/mL. (C1–C3) Xen 29 treated with NCL195 at 4 µg/mL. Arrows show peptidoglycan layer (PG), plasma
membrane (PM) and mesosome-like structures (M). NCL195 treatment of Xen29 (A600 nm = 0.1) at either 2 µg/mL (1 × MIC) or 4 µg/mL (2 × MIC) for 1 h causes
detachment of the cell wall from the cell membrane. Scale bars: (A1,B1,C1): 500 nm; (A2,B2,C2): 200 nm; (A3,B3,C3): 100 nm.
significant reduction in S. pneumoniae populations at 18 h
postinfection (p = 0.002, multiple t-tests; Figures 7C, 8) as well
as significant increase in median survival time compared to the
vehicle only control (p = 0.003; Mantel–Cox test; Figure 7D).
Furthermore, intraperitoneal administration of two doses of
NCL195 at 50 mg/kg at 2 and 6 h postinfection resulted in a
statistically significant reduction in S. aureus populations in the
blood and mouse kidneys at 6 h postinfection (p = 0.006 and
0.021, respectively, multiple t-tests; Figures 7E, 9) as well as a
significant increase in median survival time compared to the
vehicle only control (p = 0.009; Mantel–Cox test; Figure 7F). No
adverse effects attributable to drug treatment were observed in
the three rodent studies.
DISCUSSION
There is an urgent need to develop new broad-spectrum
antimicrobials with activity against pan resistant ESKAPE
pathogens, particularly Gram-negative members, with a
view to overcoming the permeability barrier of the Gram-
negative outer membrane (Willyard, 2017; Venter, 2019;
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FIGURE 6 | Selected histological images of heart, liver, spleen, and kidneys from treated and control mice. No morphological abnormalities or changes were
observed in mice subject to NCL195 (10 mg/kg), NCL195 (50 mg/kg), or daptomycin compared with PBS. Scale bars: heart: 50 µm; liver, spleen, and kidneys:
200 µm.
World Health Organization [WHO], 2019). Previously, we
reported that NCL195 showed potential as a new drug scaffold
for the treatment of infections caused by Gram-positive
bacteria on the basis of its favorable pharmacokinetic and
pharmacodynamics profile compared to the parent compound
robenidine (Ogunniyi et al., 2017). Here, we extended our
analyses by assessing in vitro efficacy of NCL195 against a range
of clinical human Gram-negative pathogens in the presence or
absence of subinhibitory concentrations of EDTA, PMBN, or
PMB and by conducting preliminary in vivo safety and efficacy
studies against two prominent Gram-positive bacteria. This
study had three major findings. First, NCL195 demonstrated
antimicrobial activity against a variety of Gram-negative ESKAPE
pathogens in the presence of outer membrane permeabilizers
(EDTA, PMB, and PMBN). In particular, combination of
NCL195 with PMB showed the best synergistic activity against
all the bacteria tested. Second, NCL195 showed systemic safety
in mice without any apparent morphological effects on the major
organs examined. However, as this study has only examined
histomorphology but not clinical chemistry and hematology,
sublethal effects not resulting in morphological changes of tissues
cannot be excluded. Third, systemic treatment of mice with
NCL195 reduced bioluminescent S. pneumoniae and S. aureus
populations in vivo and significantly prolonged survival times.
We demonstrated that the combination of EDTA with
NCL195 resulted in a synergistic interaction when tested against
E. coli, K. pneumoniae, P. putida, and P. aeruginosa type and
clinical strains. In combination, NCL195 MICs ranged from 0.5
to 8 µg/mL in the presence of EDTA concentrations ranging
from 190 to 11,400 µg/mL. However, the lowest dose of EDTA
to cause a toxic effect in animals is reported to be 750 mg/kg/day
(Lanigan and Yamarik, 2002). In addition, oral exposure to
EDTA produced adverse reproductive and developmental effects
in animals (Lanigan and Yamarik, 2002). Therefore, EDTA in
synergistic combination with NCL195 is not considered to be
a viable option for administration by the oral, intravenous, and
intramuscular routes in humans and animals.
In combination with PMBN (which alone had no
antimicrobial activity against the tested Gram-negative bacteria
except for P. aeruginosa), NCL195 exhibited a synergistic
interaction against less than half of the tested Gram-negative
bacteria, with the NCL195 MICs ranging from 4 to 32 µg/mL.
The lack of activity of PMBN against Gram-negative bacteria
has been attributed to the absence of N-terminal fatty acyl chain
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FIGURE 7 | Luminescence signal comparisons between groups of CD1 mice challenged intraperitoneally with S. pneumoniae (D39LUX) treated 6 h apart (A,B) or
treated 4 h apart (C,D), and bioluminescent S. aureus ATCC 12600 (Xen29) treated 4 h apart (E,F). Mice were subjected to bioluminescent imaging on an IVIS
Lumina XRMS Series III system. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
present in PMB and highlights the importance of both the
electrostatic and hydrophobic interactions for the mechanism
of PMB action (Velkov et al., 2010). Our results demonstrated
that the combination of PMBN with NCL195 is not ideal for
the treatment of human systemic Gram-negative bacterial
infections. PMB, with antimicrobial activity against Gram-
negative bacteria, could be a better and less expensive choice to
be used in combination with NCL195 to treat Gram-negative
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FIGURE 8 | Ventral images of representative CD1 mice challenged with approx. 1 × 107 CFU of bioluminescent S. pneumoniae (D39LUX). Mice were subjected to
bioluminescence imaging on an IVIS Lumina XRMS Series III system at the indicated times.
bacteria, reducing the required concentrations for both drugs,
and resulting in better cytotoxicity profiles (Deris et al., 2014;
Brown and Dawson, 2017; Lin et al., 2018, 2019).
Previous studies investigating the metabolic pathways
impacted by PMB alone or in combination with enrofloxacin
was carried out to discover the mechanism of action of
the combination against Gram-negative bacteria (Lin et al.,
2019). It was found that a large number of metabolites
associated with fatty acid and lipid metabolism pathways were
significantly perturbed following treatment of P. aeruginosa with
subinhibitory concentration of PMB alone or in combination
with enrofloxacin at 1 and 4 h, consistent with the mode of
action of PMB in the disruption of the bacterial outer membrane
(Lin et al., 2018, 2019). These pathways play an important role
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FIGURE 9 | Ventral and dorsal images of representative CD1 mice challenged with approx. 1 × 107 CFU of bioluminescent S. aureus ATCC 12600 (Xen29). Mice
were subjected to bioluminescence imaging on an IVIS Lumina XRMS Series III system at the indicated times.
in the DNA repair process; therefore PMB alone can disrupt
these processes to prevent the self-repair mechanisms in the
bacteria. On the other hand, we previously showed that NCL195
disrupts the inner membrane potential of Gram-positive bacteria
and inhibits DNA and RNA synthesis, thereby hindering the
establishment and maintenance of essential energy sources for
cell functioning (Ogunniyi et al., 2017). Thus, we hypothesized
that a combination of PMB and NCL195 will disrupt the outer
membrane (PMB), hence allowing penetration of NCL195 to the
inner membrane, where it will exert its mechanism of action in
preventing DNA/RNA synthesis and altering energy metabolism
and cell envelope biogenesis. The combined action of PMB
and NCL195 was expected to be synergistic, resulting in the
antimicrobial activity of the combination against Gram-negative
bacteria, as was demonstrated in the MIC results reported here.
The proposed dual mechanism of action of the NCL195-PMB
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combination was proven in this study by demonstrating a time-
dependent and NCL195 concentration-dependent disruption of
the inner membrane potential of E. coli cells.
Further screening of a broader range of clinical Gram-negative
bacteria isolated from humans (18 K. pneumoniae, 18 E. coli, 16
A. baumannii, and 19 P. aeruginosa) proved our hypothesis that
in the presence of PMB, NCL195 could inhibit the growth of
the ESKAPE pathogens (MICs ranging from 0.25 to 4 µg/mL)
(Ogunniyi et al., 2017). The current results show that the MIC of
NCL195 was significantly reduced 32- to 512-fold, and the MIC
of PMB was reduced 2- to 8-fold. Although it was previously
reported that PMB is toxic for humans at a concentration of
4 µg/mL, the lowest concentration required in combination with
NCL195 ranged from 0.0625 to 0.25 µg/mL, which is 64- to 16-
fold lower than its cytotoxic dose (Roberts et al., 2015; Ahmed
et al., 2017). Overall, PMB was the best choice among the three
outer membrane permeabilizers, due to the subinhibitory activity
against all Gram-negative species, as well as lower MICs and less
toxicity potential.
We previously used fluorescence-based membrane potential
measurements to show that NCL195 and other NCL compounds
permeabilize the cytoplasmic membrane of S. pneumoniae and
S. aureus, and hence hinder the establishment and maintenance
of essential energy sources for cell functioning (Ogunniyi et al.,
2017). In this study, we extended our investigation on the
effects of NCL195 on bioluminescent S. aureus morphology
prepared using Tokuyasu cryo-ultramicrotomy. TEM images
show membrane morphology changes and the presence of
mesosome-like membrane structures in NCL195-treated but not
in untreated bacteria. The presence of mesosomes is possibly a
consequence of cell membrane perturbation through disruption
of the membrane potential, consistent with the effects of other
antibiotic treatments reported by other workers (Friedrich et al.,
2000; Li et al., 2008; Morita et al., 2015; Gao et al., 2019).
We also found that two intraperitoneal administrations of
NCL195 at 50 mg/kg at 4 h apart was safe in mice without any
demonstrable clinical signs or observable morphological effects
on the main organs examined. Given these findings, there is a
possibility of using PMB in combination with NCL195 for human
use after appropriate testing in animal models of infection.
Based on the above, we evaluated the potential of NCL195
as a therapeutic drug against acute systemic S. pneumoniae
or S. aureus infection, using luminescent derivatives of
highly virulent pneumococcal strain (D39LUX) and S. aureus
ATCC12600 (Xen29) in an intraperitoneal challenge infection
model. Our results show that two 50 mg/kg i.p. doses of
NCL195 resulted in a statistically significant reduction in both
S. pneumoniae or S. aureus populations and prolonged survival
times compared to the vehicle-only control. These results suggest
that while plasma binding increases the MIC for NCL195 by
fourfold against S. aureus in vitro, it does not appear to affect its
in vivo activity, as judged by the statistically significant increase
in the median survival times of mice that received NCL195
compared to the vehicle only group. While NCL195 did not
achieve the level of potency seen with daptomycin, we have
shown that no resistance developed above the MIC for S. aureus
over 24 serial passages, whereas resistance to daptomycin
developed by day 5, and increased up to 8 × MIC by day 12
of the serial passage (Ogunniyi et al., 2017). A low propensity
to select resistance is a desirable characteristic for further
exploration of NCL195 as a novel antimicrobial class to treat
acute bacterial infections in humans. Furthermore, it is reported
that daptomycin, which is active against resistant Gram-positive
bacteria, does not have antimicrobial activity against most Gram-
negative bacteria, even in combination with antimicrobials and
outer membrane permeabilizers (Phee et al., 2013). Together, our
findings demonstrate that the new antibacterial class represented
by NCL195 could provide promising new scaffolds for further
pharmaceutical and medicinal chemistry development. Further
chemical diversification of the NCL195 scaffold is desirable to
increase solubility and reduce plasma binding and potential
toxicity, as well as improve potency against the antimicrobial
resistant pathogens currently listed as most urgent priority for
antibacterial drug discovery and development (Willyard, 2017;
World Health Organization [WHO], 2019).
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